Rajiv Agarwal1, Amer Joseph2, Stefan D Anker3, Gerasimos Filippatos4, Peter Rossing5,6, Luis M Ruilope7,8,9, Bertram Pitt10, Peter Kolkhof11, Charlie Scott12, Robert Lawatscheck13, Daniel J Wilson14, George L Bakris15. 1. Division of Nephrology, Department of Medicine, Richard L. Roudebush Veterans Affairs Medical Center and Indiana University, Indianapolis, Indiana ragarwal@iu.edu. 2. Cardiology and Nephrology Clinical Development, Bayer AG, Berlin, Germany. 3. Department of Cardiology (Campus Virchow-Klinikum) and Berlin Institute of Health Center for Regenerative Therapies, German Centre for Cardiovascular Research Partner Site Berlin, Charité Universitätsmedizin, Berlin, Germany. 4. National and Kapodistrian University of Athens, School of Medicine, Department of Cardiology, Attikon University Hospital, Athens, Greece. 5. Steno Diabetes Center Copenhagen, Gentofte, Denmark. 6. Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. 7. Cardiorenal Translational Laboratory and Hypertension Unit, Institute of Research imas12, Madrid, Spain. 8. Centro de Investigación Biomédia en Red Enfermedades Cardiovasculares (CIBER-CV), Hospital Universitario 12 de Octubre, Madrid, Spain. 9. Faculty of Sport Sciences, European University of Madrid, Madrid, Spain. 10. Department of Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan. 11. Research and Development, Preclinical Research Cardiovascular, Bayer AG, Wuppertal, Germany. 12. Data Science and Analytics, Bayer PLC, Reading, United Kingdom. 13. Medical Affairs & Pharmacovigilance, Pharmaceuticals, Bayer AG, Berlin, Germany. 14. US Medical Affairs, Bayer US LLC Pharmaceuticals, Whippany, New Jersey. 15. Department of Medicine, University of Chicago Medicine, Chicago, Illinois.
Abstract
BACKGROUND: Finerenone reduced risk of cardiorenal outcomes in patients with CKD and type 2 diabetes in the FIDELIO-DKD trial. We report incidences and risk factors for hyperkalemia with finerenone and placebo in FIDELIO-DKD. METHODS: This post hoc safety analysis defined hyperkalemia as ≥mild or ≥moderate based on serum potassium concentrations of >5.5 or >6.0 mmol/L, respectively, assessed at all regular visits. Cumulative incidences of hyperkalemia were based on the Aalen-Johansen estimator using death as competing risk. A multivariate Cox proportional hazards model identified significant independent predictors of hyperkalemia. Restricted cubic splines assessed relationships between short-term post-baseline changes in serum potassium or eGFR and subsequent hyperkalemia risk. During the study, serum potassium levels guided drug dosing. Patients in either group who experienced ≥mild hyperkalemia had the study drug withheld until serum potassium was ≤5.0 mmol/L; then the drug was restarted at the 10 mg daily dose. Placebo-treated patients underwent sham treatment interruption and downtitration. RESULTS: Over 2.6 years' median follow-up, 597 of 2785 (21.4%) and 256 of 2775 (9.2%) patients treated with finerenone and placebo, respectively, experienced treatment-emergent ≥mild hyperkalemia; 126 of 2802 (4.5%) and 38 of 2796 (1.4%) patients, respectively, experienced moderate hyperkalemia. Independent risk factors for ≥mild hyperkalemia were higher serum potassium, lower eGFR, increased urine albumin-creatinine ratio, younger age, female sex, β-blocker use, and finerenone assignment. Diuretic or sodium-glucose cotransporter-2 inhibitor use reduced risk. In both groups, short-term increases in serum potassium and decreases in eGFR were associated with subsequent hyperkalemia. At month 4, the magnitude of increased hyperkalemia risk for any change from baseline was smaller with finerenone than with placebo. CONCLUSIONS: Finerenone was independently associated with hyperkalemia. However, routine potassium monitoring and hyperkalemia management strategies employed in FIDELIO-DKD minimized the impact of hyperkalemia, providing a basis for clinical use of finerenone.
BACKGROUND: Finerenone reduced risk of cardiorenal outcomes in patients with CKD and type 2 diabetes in the FIDELIO-DKD trial. We report incidences and risk factors for hyperkalemia with finerenone and placebo in FIDELIO-DKD. METHODS: This post hoc safety analysis defined hyperkalemia as ≥mild or ≥moderate based on serum potassium concentrations of >5.5 or >6.0 mmol/L, respectively, assessed at all regular visits. Cumulative incidences of hyperkalemia were based on the Aalen-Johansen estimator using death as competing risk. A multivariate Cox proportional hazards model identified significant independent predictors of hyperkalemia. Restricted cubic splines assessed relationships between short-term post-baseline changes in serum potassium or eGFR and subsequent hyperkalemia risk. During the study, serum potassium levels guided drug dosing. Patients in either group who experienced ≥mild hyperkalemia had the study drug withheld until serum potassium was ≤5.0 mmol/L; then the drug was restarted at the 10 mg daily dose. Placebo-treated patients underwent sham treatment interruption and downtitration. RESULTS: Over 2.6 years' median follow-up, 597 of 2785 (21.4%) and 256 of 2775 (9.2%) patients treated with finerenone and placebo, respectively, experienced treatment-emergent ≥mild hyperkalemia; 126 of 2802 (4.5%) and 38 of 2796 (1.4%) patients, respectively, experienced moderate hyperkalemia. Independent risk factors for ≥mild hyperkalemia were higher serum potassium, lower eGFR, increased urine albumin-creatinine ratio, younger age, female sex, β-blocker use, and finerenone assignment. Diuretic or sodium-glucose cotransporter-2 inhibitor use reduced risk. In both groups, short-term increases in serum potassium and decreases in eGFR were associated with subsequent hyperkalemia. At month 4, the magnitude of increased hyperkalemia risk for any change from baseline was smaller with finerenone than with placebo. CONCLUSIONS: Finerenone was independently associated with hyperkalemia. However, routine potassium monitoring and hyperkalemia management strategies employed in FIDELIO-DKD minimized the impact of hyperkalemia, providing a basis for clinical use of finerenone.
Authors: E J Lewis; L G Hunsicker; W R Clarke; T Berl; M A Pohl; J B Lewis; E Ritz; R C Atkins; R Rohde; I Raz Journal: N Engl J Med Date: 2001-09-20 Impact factor: 91.245
Authors: Catherine M Clase; Juan-Jesus Carrero; David H Ellison; Morgan E Grams; Brenda R Hemmelgarn; Meg J Jardine; Csaba P Kovesdy; Gregory A Kline; Gregor Lindner; Gregorio T Obrador; Biff F Palmer; Michael Cheung; David C Wheeler; Wolfgang C Winkelmayer; Roberto Pecoits-Filho Journal: Kidney Int Date: 2019-10-10 Impact factor: 10.612
Authors: B M Brenner; M E Cooper; D de Zeeuw; W F Keane; W E Mitch; H H Parving; G Remuzzi; S M Snapinn; Z Zhang; S Shahinfar Journal: N Engl J Med Date: 2001-09-20 Impact factor: 91.245
Authors: Csaba P Kovesdy; Kunihiro Matsushita; Yingying Sang; Nigel J Brunskill; Juan J Carrero; Gabriel Chodick; Takeshi Hasegawa; Hiddo L Heerspink; Atsushi Hirayama; Gijs W D Landman; Adeera Levin; Dorothea Nitsch; David C Wheeler; Josef Coresh; Stein I Hallan; Varda Shalev; Morgan E Grams Journal: Eur Heart J Date: 2018-05-01 Impact factor: 29.983
Authors: Bertram Pitt; Lars Kober; Piotr Ponikowski; Mihai Gheorghiade; Gerasimos Filippatos; Henry Krum; Christina Nowack; Peter Kolkhof; So-Young Kim; Faiez Zannad Journal: Eur Heart J Date: 2013-05-27 Impact factor: 29.983
Authors: Gerasimos Filippatos; Stefan D Anker; Rajiv Agarwal; Bertram Pitt; Luis M Ruilope; Peter Rossing; Peter Kolkhof; Patrick Schloemer; Ingo Tornus; Amer Joseph; George L Bakris Journal: Circulation Date: 2020-11-16 Impact factor: 29.690
Authors: Martin Gritter; Rosa D Wouda; Stanley M H Yeung; Michiel L A Wieërs; Frank Geurts; Maria A J de Ridder; Christian R B Ramakers; Liffert Vogt; Martin H de Borst; Joris I Rotmans; Ewout J Hoorn Journal: J Am Soc Nephrol Date: 2022-05-24 Impact factor: 14.978
Authors: Michele Provenzano; Maria Jesús Puchades; Carlo Garofalo; Niels Jongs; Luis D'Marco; Michele Andreucci; Luca De Nicola; Jose Luis Gorriz; Hiddo J L Heerspink Journal: J Am Soc Nephrol Date: 2022-04-19 Impact factor: 14.978